BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (NASDAQ:INZY) ("the Company" or "Inozyme"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced a data presentation and sponsored symposium at the 11th International Conference on Children's Bone Health (ICCBH), which is being held June 22-25, 2024, in Salzburg, Austria.
Presentation Details
Title: Expanding the spectrum of radiographic features in children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency: Novel skeletal findings from an international collaboration
Format: Oral Presentation – Session 3
Date: Monday, June 24, 2024
Session Time: 11:00 – 12:00 CEST / 5:00 am – 6:00 am ET
Presenting Author: Leanne Ward, M.D., Professor of Pediatrics in the Faculty of Medicine, University of Ottawa
Symposium Details
Title: Recognizing ENPP1 Deficiency - An overlooked cause of hypophosphatemic rickets
Date: Saturday, June 22, 2024
Session Time: 13:45 – 14:45 CEST / 7:45 am – 8:45 am ET
Chair:
- Agnes Linglart, M.D., Professor of Paediatrics at the Bicetre Paris Saclay University and Hospital, and National Coordinator of the ...